Takeda Pharmaceutical Company Limited

TAKEDA PHARMACEUTICAL CO LTD is a global biopharmaceutical company focused on discovering and delivering life-transforming treatments. The company's core therapeutic areas include gastrointestinal and inflammation, neuroscience, and oncology, alongside its plasma-derived therapies (PDT) and vaccines business. TAKEDA aims to translate scientific research into innovative medicines. The company operates a geographically diversified global business, marketing its prescription drugs worldwide. It employs approximately 47,000 people globally. TAKEDA's commercial efforts are concentrated on six key business areas: GI, Rare Diseases, PDT, Oncology, Vaccines, and Neuroscience. These areas collectively generated 95.0% of the company's total revenue in the fiscal year ended March 31, 2026. Key growth driver products as of March 31, 2026, include ENTYVIO, EOHILIA, TAKHZYRO, LIVTENCITY, ADZYNMA, Immunoglobulin products (such as GAMMAGARD LIQUID/KIOVIG, HYQVIA, and CUVITRU), Albumin products (including HUMAN ALBUMIN/FLEXBUMIN), FRUZAQLA, ALUNBRIG, and QDENGA. TAKEDA's research and development (R&D) engine primarily focuses on its three core therapeutic areas: Gastrointestinal and Inflammation, Neuroscience, and Oncology, with additional targeted R&D investments in PDT. These R&D efforts aim to produce new molecular entities that represent potential best-in-class or first-in-class medicines for areas with high unmet medical needs.